Abstract Number: 693 • 2013 ACR/ARHP Annual Meeting
Pulmonary Involvement In Mixed Connective Tissue Disease: Slow Progression After 10 Years Of Follow-Up
Background/Purpose: Evaluate the progression of interstitial lung disease (ILD) in a 10-year period of a group of 53 MCTD patients previously evaluated 10 years ago.Methods:…Abstract Number: 694 • 2013 ACR/ARHP Annual Meeting
Peripheral Bone Marrow-Derived Endothelial Progenitor Cells and N-Terminal Probrain Natriuretic Peptide in Scleroderma Mexican Patients With and Without Diastolic Dysfunction: A Preliminary Report
Background/Purpose: Diastolic dysfunction (DD) in systemic sclerosis (SSc) is a marker of increased risk of death. The N-terminal pro-brain natriuretic peptide (NT-proBNP) is a neurohormone…Abstract Number: 695 • 2013 ACR/ARHP Annual Meeting
Combined Pulmonary Fibrosis and Emphysema (CPFE) In Systemic Sclerosis
Combined pulmonary fibrosis and emphysema (CPFE) in systemic sclerosis Background/Purpose: Combined pulmonary fibrosis and emphysema (CPFE) is a recently defined syndrome, in which centrilobular and/or…Abstract Number: 696 • 2013 ACR/ARHP Annual Meeting
Chronic Periaortitis With Thoracic Aorta Involvement: A New Subtype Of Large Vessel Vasculitis
Background/Purpose: Chronic periaortitis (CP) is characterised by a fibroinflammatory tissue arising from the adventitia of the abdominal aorta and the iliac arteries and spreading into…Abstract Number: 697 • 2013 ACR/ARHP Annual Meeting
Longitudinal Assessment Of Pulmonary Function In 304 Norwegian Patients With Systemic Sclerosis
Background/Purpose: The purpose of this study was to asses sequential pulmonary function measurements (forced vital capacity [FVC] % predicted) in a large systemic sclerosis (SSc)…Abstract Number: 698 • 2013 ACR/ARHP Annual Meeting
Adverse Events With The Use Of Radiotherapy In Patients With Connective Tissue Diseases and Cancer: A Systematic Review and Meta-Analysis
Background/Purpose: In the era of modern medicine, radiotherapy remains a cornerstone for the multi-modality cancer treatment. Methods: We conducted a comprehensive search for any study…Abstract Number: 699 • 2013 ACR/ARHP Annual Meeting
Severity Of Muscle Weakness Predicts Disability In Scleroderma
Title: Severity of muscle weakness predicts disability in scleroderma Background/Purpose: The Health assessment questionnaire disability index (HAQ-DI) is a self-administered questionnaire that is a patient…Abstract Number: 700 • 2013 ACR/ARHP Annual Meeting
Osteoporosis and Fracture Risk In Outpatients With Systemic Sclerosis
Background/Purpose: Osteoporosis (OP) is a frequent complication of a number of chronic inflammatory diseases. Only Rheumatoid Arthritis (RA) is included in the FRAX algorythm to…Abstract Number: 701 • 2013 ACR/ARHP Annual Meeting
Extension Of Cardiac Damage Through The Delayed Enhancement Of Cardiac Magnetic Resonance: Predictive Value Of a Combined Approach Based On Clinical and Laboratory Findings, EKG-Holter and Cardiac Magnetic Resonance
Background/Purpose: Cardiac involvement is a relevant prognostic determinant in Systemic Sclerosis (SSc), but the diagnosis is often delayed due to the lack of a specific…Abstract Number: 702 • 2013 ACR/ARHP Annual Meeting
Prediction Of Worsening Of Skin Fibrosis In Patients With Diffuse Systemic Sclerosis Using The EULAR Scleroderma Trials and Research (EUSTAR) Registry
Background/Purpose: To identify predictive parameters for the progression of skin fibrosis in patients with diffuse cutaneous SSc (dcSSc) to enable 1) risk-stratification in clinical practice…Abstract Number: 703 • 2013 ACR/ARHP Annual Meeting
Correlation Between Patient Self-Report Of Symptoms Of Raynaud’s Phenomenon and Objective Assessment Of Digital Microvascular Perfusion Using Infrared Thermography
Background/Purpose: Patient self-report of digital colour changes form the basis of a clinical diagnosis of Raynaud's phenomenon (RP) and help classify patients with early systemic…Abstract Number: 704 • 2013 ACR/ARHP Annual Meeting
Evaluating The Effects Of Combination Aspirin and Dipyridamole (asasantin retard) On Platelet Function, Oxidative Stress and Peripheral Vascular Function In Primary Raynaud’s Phenomenon and Systemic Sclerosis
Background/Purpose: There is evidence of enhanced platelet activation in Raynaud’s phenomenon (RP), particularly in systemic sclerosis (SSc). Upon activation, platelets release vasoconstrictive mediators (e.g. thromboxane…Abstract Number: 705 • 2013 ACR/ARHP Annual Meeting
Treatment With Rituximab Reduces Activation Of Scleroderma Dermal Fibroblasts
Background/Purpose: There is evidence that B lymphocytes play a role in the pathogenesis of systemic sclerosis (scleroderma). Stimulatory autoantibodies targeting PDGF receptor and activating normal…Abstract Number: 706 • 2013 ACR/ARHP Annual Meeting
Effect Of Aminaftone On Raynaud’s Phenomenon Secondary To Systemic Sclerosis: A Double-Blind Prospective, Randomized, Placebo-Controlled Pilot Study
Background/Purpose: Raynaud’s phenomenon (RP) is a pivotal manifestation of systemic sclerosis (SSc) which reflects an underlying vasculopathy. Endothelial activation with increased circulating levels of Endothelin-1…Abstract Number: 663 • 2013 ACR/ARHP Annual Meeting
Propylthiouracil Attenuates Aortic Vasculopathy In An Animal Model Of Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a generalized connective tissue disorder of unknown etiology characterized by thickening and fibrosis of the skin and distinctive visceral involvement…
ACR Meeting Abstracts